Literature DB >> 30740443

RAD51 paralogs promote genomic integrity and chemoresistance in cancer by facilitating homologous recombination.

Janelle Louise Harris1, Andrea Rabellino1, Kum Kum Khanna1.   

Abstract

Entities:  

Year:  2018        PMID： 30740443      PMCID： PMC6330604          DOI： 10.21037/atm.2018.12.30

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  30 in total

1.  Identification and purification of two distinct complexes containing the five RAD51 paralogs.

Authors:  J Y Masson; M C Tarsounas; A Z Stasiak; A Stasiak; R Shah; M J McIlwraith; F E Benson; S C West
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

Review 3.  XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review.

Authors:  Maurizio Manuguerra; Federica Saletta; Margaret R Karagas; Marianne Berwick; Fabrizio Veglia; Paolo Vineis; Giuseppe Matullo
Journal:  Am J Epidemiol       Date:  2006-05-17       Impact factor: 4.897

4.  Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

Authors:  Anand G Patel; Jann N Sarkaria; Scott H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

Review 5.  Regulation of homologous recombination in eukaryotes.

Authors:  Wolf-Dietrich Heyer; Kirk T Ehmsen; Jie Liu
Journal:  Annu Rev Genet       Date:  2010       Impact factor: 16.830

6.  Homologous pairing and ring and filament structure formation activities of the human Xrcc2*Rad51D complex.

Authors:  Hitoshi Kurumizaka; Shukuko Ikawa; Maki Nakada; Rima Enomoto; Wataru Kagawa; Takashi Kinebuchi; Mitsuyoshi Yamazoe; Shigeyuki Yokoyama; Takehiko Shibata
Journal:  J Biol Chem       Date:  2002-02-07       Impact factor: 5.157

7.  The ATPase motif in RAD51D is required for resistance to DNA interstrand crosslinking agents and interaction with RAD51C.

Authors:  Aaron M Gruver; Kristi A Miller; Changanamkandath Rajesh; Phillip G Smiraldo; Saravanan Kaliyaperumal; Rachel Balder; Katie M Stiles; Joanna S Albala; Douglas L Pittman
Journal:  Mutagenesis       Date:  2005-10-19       Impact factor: 3.000

8.  Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs.

Authors:  M Takata; M S Sasaki; S Tachiiri; T Fukushima; E Sonoda; D Schild; L H Thompson; S Takeda
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

9.  Domain mapping of the Rad51 paralog protein complexes.

Authors:  Kristi A Miller; Dorota Sawicka; Daniel Barsky; Joanna S Albala
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

10.  Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice.

Authors:  Sergey G Kuznetsov; Diana C Haines; Betty K Martin; Shyam K Sharan
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701
View more
  2 in total

1.  Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis.

Authors:  Jillian C Jacobson; Jingbo Qiao; Rachael A Clark; Dai H Chung
Journal:  Discov Oncol       Date:  2022-10-13

2.  Regulation and pharmacological targeting of RAD51 in cancer.

Authors:  McKenzie K Grundy; Ronald J Buckanovich; Kara A Bernstein
Journal:  NAR Cancer       Date:  2020-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.